Skip to main content

Table 1 Demographics of patients included in the analysis

From: Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Patient characteristics Drug Placebo P value
(n = 4) (n = 5)
Age (years) 54.5 ± 17.3 58.8 ± 9.5 0.64
Sex (F, n) 1 1 0.99
BMI 30.15 ± 5.1 28.8 ± 5.9 0.72
FEV1 %predicted 60 ± 15.5 51.6 ± 13.1 0.41
FEV1/VC 0.64 ± 0.15 0.56 ± 0.09 0.36
Serum IgE 965 ± 1499 482 ± 696 0.58
ACQ-5 1.79 ± 0.5 2.2 ± 0.67 0.35
Blood eosinophil (× 109/L) 0.35 ± 0.23 0.62 ± 0.50 0.36
Sputum eosinophil (%) 15.75 ± 11.1 22.18 ± 14.02 0.5
Prednisone use (n) 1 (4) 0 0.29
Inhaled corticosteroid (median, max–min) 1450 (2000, 800) 1500 (2400, 1250) 0.37
  1. N.B. data presented as mean ± standard deviation, unless otherwise mentioned. All patients were skin prick test positive